WashU Pipeline

See below for a summary of products, either in development or on the market, that incorporate Washington University IP.  For more information on the product or the licensing partner, click on the links provided.

Therapeutics
ProductLicenseePreclinical Phase IPhase II Phase III NDA Market
σ-2 Receptor TargetingAccuronix TherapeuticsPreclinical
UTI O-MannosideFimbrion Therapeutics, Inc.Preclinical
UTI C-Mannoside
Fimbrion Therapeutics, Inc.
Preclinical
Factor-VIIa-CTPOpko Biologics (Modigene)
hGH-CTPOpko Biologics (Modigene)
Long-Acting OxyntomodulinOpko Biologics (Modigene)
ABBV-8E12C2N Diagnostics
Modified pyrazolopyrimidine (PP) InhibitorsTuring
Device Products
ProductLicenseePreclinical Phase IPhase II Phase III NDA Market
Cerafix® Dura SubstituteAcera SurgicalPhase I
Inferior Nodal Extension PacingCardialen, Inc.Preclinical
Atrial Unpinning Pulse Termination TherapyCardialen, Inc.Phase I
Ventricular Unpinning Pulse Termination TherapyCardialen, Inc.Phase I
Next-Gen Air FiltrationApplied Particle TechnologyPhase I
Brain Computer Interface (BCI) TechnologyNeurolutionsPhase I
COMPUTING/Software
ProductLicenseePreclinical Phase IPhase II Phase III NDA Market
VarScanAppistry
Customized Hearing HealthcareclEAR, LLC
Exegy Ticker PlantExegy
Exegy Trading Application Platform (TAP)Exegy
Exegy Market Data SystemExegy
Exegy Data ToneExegy
2-1-1 CountsHealth Communication Impact, LLC
VortexVelocidata
RaptorVelocidata
Diagnostics
ProductLicenseePreclinical Phase IPhase II Phase III NDA Market
SILK-Aβ® (Total)C2N Diagnostics, LLC
SILK-Aβ® (Isoforms)C2N Diagnostics, LLC
SILK-Aβ® SPOT (Companion Dx Test)C2N Diagnostics, LLC
SILK-ApoE™ (Isoforms)C2N Diagnostics, LLC
SILK-sAPP™ (sAPPα and β)C2N Diagnostics, LLC
SISAQ-Aβ™ (Aβ Total and Isoforms)C2N Diagnostics, LLC
SISAQ™-Multi-Analyte Dementia PanelC2N Diagnostics, LLC
SILK-SOD1™C2N Diagnostics, LLC
Gene detecting Cancer in Melanoma PatientsCastle BioSciences Inc.
MyoglobinSiemens (fmk Dade Behring Inc.)
Elvis®Diagnostic Hybrids (Quidel Corporation)
Cancer Antigens Targeting TIP1 and GRP78Medical Guidance Systems LLC
Consumer Products
ProductLicenseePreclinical Phase IPhase II Phase III NDA Market
Niagen®
ChromaDex, Inc.